Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 11:52 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1177–1200 of 4,803 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Sensitivity Clear all
Completed Phase 1Phase 2 Interventional Results available

Study to Evaluate the Bronchoprotective Effects of a Single Dose of N6022 in Patients With Mild Asthma

NCT01316315
View directory record Official record
Conditions
Asthma
Interventions
Active, Placebo
Drug
Lead sponsor
Nivalis Therapeutics, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
2
States / cities
Denver, Colorado • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 5, 2014 · Synced Oct 25, 2026, 11:52 PM EDT
Completed Not applicable Interventional

GI Alpha-Gal Study

NCT06268717
View directory record Official record
Conditions
Alpha-Gal Syndrome, Irritable Bowel Syndrome, Diarrhea, Abdominal Pain, Vomiting
Interventions
Ground pork containing alpha-gal, Pork meat not containing alpha-gal
Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 99 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Oct 25, 2026, 11:52 PM EDT
Completed Phase 3 Interventional

BE Study of Albuterol Sulfate Inhalation Aerosol 90 mcg Per Actuation in Patients With Stable Mild Asthma

NCT06154304
View directory record Official record
Conditions
Bronchial Asthma
Interventions
Albuterol Sulfate Inhalation Aerosol (90 mcg per actuation), Ventolin HFA 90Mcg/Actuation Inhalation Aerosol_#1, Ventolin HFA, 90 Mcg/Inh Inhalation Aerosol_#2, Placebo
Drug
Lead sponsor
Cipla Ltd.
Industry
Eligibility
18 Years to 65 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Medford, Oregon
Source: ClinicalTrials.gov public record
Updated Jul 16, 2025 · Synced Oct 25, 2026, 11:52 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Hematopoietic Stem Cell Support in Patients With Refractory Sarcoidosis

NCT00282438
View directory record Official record
Conditions
Sarcoidosis
Interventions
Autologous hematopoietic stem cell transplantation, Allogeneic stem cell transplantation
Biological
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 60 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2015
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 31, 2018 · Synced Oct 25, 2026, 11:52 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Study of Topically Applied DS107 Cream in Mild to Moderate Atopic Dermatitis Patients (AD)

NCT02925793
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
DS107, Vehicle cream
Drug · Other
Lead sponsor
DS Biopharma
Industry
Eligibility
18 Years and older
Enrollment
327 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
East Windsor, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 22, 2022 · Synced Oct 25, 2026, 11:52 PM EDT
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

Adaptive Immune Response in Visceral and Subcutaneous Fat: Role in Human Insulin Resistance

NCT04708535
View directory record Official record
Conditions
Insulin Resistance, Insulin Sensitivity, Obesity, Inflammation
Interventions
Not listed
Lead sponsor
Stanford University
Other
Eligibility
30 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2026
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Oct 25, 2026, 11:52 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Gender- and Culturally-Sensitive Weight Loss Intervention for Hispanic Males

NCT02783521
View directory record Official record
Conditions
Overweight, Obesity
Interventions
Counseling sessions, Wait List Control
Behavioral
Lead sponsor
University of Arizona
Other
Eligibility
18 Years to 64 Years · Male only
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Nov 1, 2017 · Synced Oct 25, 2026, 11:52 PM EDT
Withdrawn Not applicable Interventional

Fatty Acids in Airway Smooth Muscle of Asthmatics

NCT02809235
View directory record Official record
Conditions
Asthma
Interventions
coconut oil
Dietary Supplement
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 23, 2024 · Synced Oct 25, 2026, 11:52 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

The Leaky Lung Test

NCT02306473
View directory record Official record
Conditions
Asthma, Allergy, Reactive Airway Disease, Lung Diseases, Obstructive
Interventions
Mannitol
Drug
Lead sponsor
University of Rochester
Other
Eligibility
18 Years to 80 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jan 4, 2018 · Synced Oct 25, 2026, 11:52 PM EDT
Completed Phase 4 Interventional

Epiceram Versus Elidel for Treatment of Mild to Moderate Atopic Dermatitis

NCT00460083
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Elidel(R) (pimecrolimus 1%), EpiCeram(R) -ceramide based barrier repair cream
Drug · Device
Lead sponsor
Ceragenix Pharmaceuticals
Industry
Eligibility
2 Years to 12 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
2
States / cities
San Diego, California • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Feb 6, 2008 · Synced Oct 25, 2026, 11:52 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Exposure of Budesonide, Glycopyrronium, and Formoterol (BGF) Delivered by Hydrofluoroolefin (HFO) Propellant Metered Dose Inhaler (MDI) Compared to a Hydrofluoroalkane (HFA) Propellant MDI in Healthy Adults

NCT06723756
View directory record Official record
Conditions
Healthy Participants
Interventions
Treatment A: BGF MDI HFO, Treatment B: BGF MDI HFA
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 60 Years
Enrollment
105 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Brooklyn, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 5, 2025 · Synced Oct 25, 2026, 11:52 PM EDT
Terminated Phase 1 Interventional

CNP-201 in Subjects With Peanut Allergy

NCT05250856
View directory record Official record
Conditions
Peanut Allergy
Interventions
CNP-201, Placebo
Drug
Lead sponsor
COUR Pharmaceutical Development Company, Inc.
Industry
Eligibility
16 Years to 55 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
17
States / cities
Birmingham, Alabama • Long Beach, California • Mission Viejo, California + 13 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2023 · Synced Oct 25, 2026, 11:52 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Early Introduction and Sustained Ingestion (EISI) Using Two Educational Opportunities in Infants

NCT07321522
View directory record Official record
Conditions
Food Allergy
Interventions
Education and Opportunities on Early Introduction, Clinician Supervised Feeding of Known Allergenic Food
Behavioral
Lead sponsor
Stanford University
Other
Eligibility
4 Months to 11 Months
Enrollment
92 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jun 26, 2026 · Synced Oct 25, 2026, 11:52 PM EDT
Completed Not applicable Interventional

Sponge and Eosinophil Peroxidase (EPO) Staining

NCT03078023
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
swallowed sponge device
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 70 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 15, 2022 · Synced Oct 25, 2026, 11:52 PM EDT
Completed Phase 3 Interventional Results available

5-Year Safety Study of Pimecrolimus Cream 1% in Infants 3 - 12 Months of Age With Mild to Moderate Atopic Dermatitis

NCT00120523
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Pimecrolimus, Topical corticosteroids
Drug
Lead sponsor
MEDA Pharma GmbH & Co. KG
Industry
Eligibility
3 Months to 12 Months
Enrollment
2,418 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
30
States / cities
Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 25 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2022 · Synced Oct 25, 2026, 11:52 PM EDT
Completed Phase 4 Interventional Results available

A 24-Week Treatment Study to Compare Standard of Care Versus the eMDPI DS in Participants 13 Years or Older With Asthma

NCT04677959
View directory record Official record
Conditions
Asthma
Interventions
Fluticasone propionate/salmeterol (FS), Albuterol, Standard of Care Asthma Medication, Standard of Care Rescue Medication
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
13 Years and older
Enrollment
427 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
46
States / cities
Phoenix, Arizona • Fountain Valley, California • Los Angeles, California + 37 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2023 · Synced Oct 25, 2026, 11:52 PM EDT
Completed Phase 4 Interventional Results available

Biomarker Predictors of Memantine Sensitivity in Patients With Alzheimer's Disease

NCT03703856
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Memantine
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
50 Years to 83 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Oct 25, 2026, 11:52 PM EDT
Completed Not applicable Interventional Results available

Using Technology-Assisted Stepped Care Intervention to Improve Adherence in Adolescents With Asthma

NCT04365556
View directory record Official record
Conditions
Asthma
Interventions
TASC Intervention
Behavioral
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
12 Years to 18 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 18, 2025 · Synced Oct 25, 2026, 11:52 PM EDT
Completed Phase 3 Interventional Results available

Efficacy of Inhaled Albuterol Spiromax® in Subjects With Persistent Asthma With Steady State Pharmacokinetics

NCT01747629
View directory record Official record
Conditions
Asthma
Interventions
Placebo MDPI, Albuterol MDPI
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
12 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
35
States / cities
Costa Mesa, California • Encinitas, California • Huntington Beach, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2015 · Synced Oct 25, 2026, 11:52 PM EDT
Withdrawn Not applicable Interventional

A New Wizard for Insulin Sensitivity Estimation From SAP: a Randomized Controlled Trial in Adolescents With T1D

NCT03034759
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
individualized insulin sensitivity index (ISind)
Other
Lead sponsor
Yale University
Other
Eligibility
12 Years to 21 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 11, 2019 · Synced Oct 25, 2026, 11:52 PM EDT
Completed Not applicable Interventional Results available

Dietary Supplementation With Soy Isoflavones in Asthma

NCT00277446
View directory record Official record
Conditions
Asthma
Interventions
Soy isoflavones
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 50 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 25, 2011 · Synced Oct 25, 2026, 11:52 PM EDT
Completed Phase 2 Interventional

Open-Label Trial of the Use of Minocycline in the Treatment of Asthma

NCT00536042
View directory record Official record
Conditions
Asthma
Interventions
Minocycline
Drug
Lead sponsor
State University of New York - Downstate Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2009
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Mar 10, 2020 · Synced Oct 25, 2026, 11:52 PM EDT
Completed Not applicable Interventional

Rapid Acute Coronary Syndrome Exclusion Using High-sensitivity I Troponin

NCT04488913
View directory record Official record
Conditions
Chest Pain, Myocardial Ischemia
Interventions
RACE-IT Pathway, Standard of Care
Other
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years and older
Enrollment
32,609 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 23, 2022 · Synced Oct 25, 2026, 11:52 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Xolair Enhances Oral Desensitization in Peanut Allergic Patients

NCT01290913
View directory record Official record
Conditions
Peanut Allergy
Interventions
Omalizumab
Drug
Lead sponsor
Lynda Schneider
Other
Eligibility
7 Years to 25 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 7, 2015 · Synced Oct 25, 2026, 11:52 PM EDT